Skip to main content
. 2022 Jul 14;10(7):1701. doi: 10.3390/biomedicines10071701

Table 1.

Clinical characteristics of patients with IC/BPS and the control patients.

IC/BPS
ESSIC Type 1
(N = 42, 26.4%)
ESSIC Type 2
(N = 117, 73.6%)
Overall
(N = 159, 100%)
Control
(N = 28)
p-Value * p-Value #
Age 56.9 ± 10.9
(28–78)
53.5 ± 13.2
(21–88)
54.4 ± 12.7
(21–88)
58.6 ± 9.9
(39–75)
0.145 0.101
Sex F40, M2 F99, M18 F139, M20 F 28 0.075 0.048
DM 8 (19.0%) 10 (8.5%) 18 (11.3%) 5 (17.9%) 0.087 0.350
BMI 25.88 ± 4.24 23.00 ± 4.07 23.76 ± 4.30 25.66 ± 4.03 <0.001 0.031
VAS 4.4 ± 2.6 4.5 ± 2.8 4.5 ± 2.7 0.766
ICSI 9.8 ± 4.7 10.9 ± 4.3 10.6 ± 4.4 0.194
ICPI 10.4 ± 4.5 10.7 ± 3.7 10.6 ± 3.9 0.625
OSS 20.2 ± 8.8 21.7 ± 7.5 21.3 ± 7.8 0.272
MBC (mL) 782.1 ± 192.5 711.1 ± 176.8 729.9 ± 183.2 0.031

Note: DM, diabetes mellitus; BMI, body mass index; VAS, visual analog scale; ICSI, interstitial cystitis symptom index; ICPI, interstitial cystitis problem index; OSS, O’Leary-Saint score; MBC, maximal bladder capacity under anesthesia. *: p-values between ESSIC type 1 and type 2 IC/BPS patients. #: p-values between overall IC/BPS patients and controls.